SmartTest acquires FMCSA accident app to aid TPA's and clients.



Post-Accident Testing Smartphone App Alerts TPA’s and Clients to Accidents
Smart Test is happy too announce the acquisition and release of the freeFMCSA Accident app.
FMCSA Accident is a straightforward, user-friendly, professional-grade smartphone app that ensures compliant decisions are made after accidents. FMCSA Accident is a free app.
FMCSA Accident allows you to easily determine if an accident is covered by FMCSA and directs you to either administer federal post-accident drug and alcohol testing or NON-DOT testing.
· You will be alerted to your client’s/employees testing requirements instantly, by email, text, or both. A description of the accident will tell you what type of test is required, allowing you to monitor the process, advise the client for compliance, alert the collection site, and invoice accordingly.
· Ensure that all of your client’s/employees require their drivers to list your email in the set-up page, and you will be in the loop.
· Give your client’s/employees more while increasing your own monitoring capabilities.
Fast & Authoritative Decisions: Analyzing an accident on FMSCA Accident is intuitive. Simply navigate through a few critical questions to determine if federally mandated testing thresholds have been met.
Alerts and Monitoring: Once the decisions are made, a summary email is sent to the DER, Supervisors, Third Party Administrator, etc., with a brief description of the accident. Testing instructions, time-limits, and federal requirements are clearly displayed.
No frills, no confusion…just sharing information with the decision makers who matter most to this process.
FMCSA Accident is free and available for iPhone and for Android.
Download for free today.
Smart Test
240 Commercial St.
Boston, MA 02109
617–963–8378
Location: 240 Commercial St., FL 3, Boston, MA 02109, United States

Comments

Post a Comment

Popular posts from this blog

Patrice Kelly named Director of ODAPC

Patrice Kelly, former Acting Director of the Drug of Alcohol Policy and Compliance (ODAPC) has been named Director of ODAPC . Her directorship comes at the best-possible time for public safety, as the USDOT plans to allow for the testing of an expanded opioid panel in the current five panel tests currently mandated. Under her role as Acting Director, ODAPC increased public outreach, fostered safety program improvements in industry, and was central in guiding all DOT modes through the changing state laws regarding cannabis and the opioid crisis. The industry can expect Director Kelly and her team at ODAPC to continue to provide guidance and clarification to transportation safety in a rapidly changing landscape, and to lead a safety program which directly impacts the US roads, skies, waterways, and pipelines. Smart Test 240 Commercial St. Boston MA 02109
Read more

DNA Testing In Boston

Image
The rise of affordability on DNA testing has allowed for substantial increases in its applicability.  From DNA testing for US Immigration to testing for ancestry research and maternity/paternity cases, the biggest obstacles to testing are the cost of the test, the reliability and defensibility of the results, and the timeframe to receive results. Following testing protocols without error at the time of collection are required for a specimen to be valid and defensible, and a laboratory which can provide fast-yet-accurate results. Popular DNA testing services for ancestry can take up to eight weeks and paternity tests can take several weeks. Smart Test provides affordable testing with legally valid results in under a week. DNA testing in Boston is now faster, more accurate, secure and confidential at an affordable price. Smart Test Boston (617) 963–8378 240 Commercial St. Boston, MA 02109
Read more

Oral Fluids Testing — Current Barriers to USDOT Approval

Image
Oral Fluids Testing — Current Barriers to USDOT Approval Oral fluids testing offered by several national drug testing labs ( Quest , Alere , and Omega for example) provides a new method for the detection of metabolites for drug testing, but is not currently approved for use by the USDOT. One barrier that currently exists is that the USDOT requires the ability to split each specimen. Two oral fluid testing devices would be considered two separate specimens in the eyes of the DOT, and therefor unacceptable. One clear solution is for the collection swab to be split into two pieces and be deposited into two vials, just like a urine specimen. For this to work, it must be built into the device, as manually cutting the swab would risk contamination. Another problem faced by the labs is in the collection process itself. The current methods mostly involve the employee (or “donor”) handling the specimen collection device and to place the swab into the vials, with the collector...
Read more